Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors

BACKGROUND: Omaveloxolone is a semisynthetic oleanane triterpenoid that potently activates Nrf2 with subsequent antioxidant function. We conducted a first-in-human Phase I clinical trial (NCT02029729) with the primary objectives to determine the appropriate dose for Phase II studies, characterize ph...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Creelan, Ben C, Gabrilovich, Dmitry I, Gray, Jhanelle E, Williams, Charles C, Tanvetyanon, Tawee, Haura, Eric B, Weber, Jeffrey S, Gibney, Geoffrey T, Markowitz, Joseph, Proksch, Joel W, Reisman, Scott A, McKee, Mark D, Chin, Melanie P, Meyer, Colin J, Antonia, Scott J
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2017
Assuntos:
Clinical Trial Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5587199/
https://ncbi.nlm.nih.gov/pubmed/28919776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S136992
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados